{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:17:59Z","timestamp":1778505479878,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000039"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000039"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"European Commission Seventh Framework Programme for Research and Technological Development Health","doi-asserted-by":"publisher","award":["305507"],"award-info":[{"award-number":["305507"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.repc.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T23:35:37Z","timestamp":1774136137000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial"],"prefix":"10.1016","volume":"45","author":[{"given":"In\u00eas","family":"Aguiar-Neves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia O.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Pedro Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hazebroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job A.J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Cuthbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Fontes-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2025.12.010_bib0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1745-0179-1-19","article-title":"Heart failure and health related quality of life","volume":"1","author":"Coelho","year":"2005","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.repc.2025.12.010_bib0335","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10741-019-09890-2","article-title":"Quality of life of chronic heart failure patients: a systematic review and meta-analysis","volume":"25","author":"Moradi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.repc.2025.12.010_bib0340","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2005.11.069","article-title":"A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the \u201cpatient journey\u201d) in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)","volume":"47","author":"Cleland","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0345","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ejhf.55","article-title":"Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies","volume":"16","author":"Mastenbroek","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0350","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.12.010_bib0355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017278","article-title":"Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure","volume":"9","author":"Sepehrvand","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2025.12.010_bib0360","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ejhf.2508","article-title":"Quality of life assessed 6\u00a0months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)","volume":"24","author":"McNaughton","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0365","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ijcard.2015.09.076","article-title":"Exploring quality of life in patients with and without heart failure","volume":"202","author":"Zhang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0370","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1053-2498(01)00298-4","article-title":"Preferences for quality of life or survival expressed by patients with heart failure","volume":"20","author":"Lewis","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.repc.2025.12.010_bib0375","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11886-021-01588-y","article-title":"Improving quality of life in heart failure","volume":"23","author":"Freedland","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.repc.2025.12.010_bib0380","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjqcco\/qcy061","article-title":"Does heart failure-specific health status identify patients with bothersome symptoms, depression, anxiety, and\/or poorer spiritual well-being?","volume":"5","author":"Flint","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.repc.2025.12.010_bib0385","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ehjqcco\/qcz009","article-title":"Quality of life in heart failure: screening alone is insufficient","volume":"5","author":"Cavanagh","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.repc.2025.12.010_bib0390","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.12.010_bib0395","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007761","article-title":"Risk-based approach for the prediction and prevention of heart failure","volume":"14","author":"Sinha","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0400","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000222","article-title":"Clinical prediction of incident heart failure risk: a systematic review and meta-analysis","volume":"2","author":"Yang","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.repc.2025.12.010_bib0405","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/eurheartj\/ehab082","article-title":"The struggle towards a Universal Definition of Heart Failure \u2013 how to proceed?","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2025.12.010_bib0410","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2019.03.471","article-title":"Prevention or procrastination for heart failure? Why we need a universal definition of heart failure","volume":"73","author":"Cleland","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0415","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ejhf.1716","volume":"22","author":"Pellicori","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0420","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2025.12.010_bib0425","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0430","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"Group EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.repc.2025.12.010_bib0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.repc.2025.12.010_bib0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.repc.2025.12.010_bib0445","series-title":"R: a language and environment for statistical computing","year":"2021"},{"key":"10.1016\/j.repc.2025.12.010_bib0450","series-title":"eq5d: methods for analysing \u2018EQ-5D\u2019 data and calculating \u2018EQ-5D\u2019 index scores. Version R package version 0.10.1","author":"Morton","year":"2021"},{"key":"10.1016\/j.repc.2025.12.010_bib0455","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jchf.2015.09.015","article-title":"Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis","volume":"4","author":"Echouffo-Tcheugui","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0460","article-title":"Subclinical alterations in left ventricular structure and function according to obesity and metabolic health status","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2025.12.010_bib0465","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ahj.2011.01.003","article-title":"Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters: quality of life in diastolic dysfunction","volume":"161","author":"Edelmann","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2025.12.010_bib0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach","volume":"6","author":"Gallagher","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0475","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.0889-7204.2005.04649.x","article-title":"Predictors of health status for heart failure patients","volume":"20","author":"De Jong","year":"2005","journal-title":"Prog Cardiovasc Nurs"},{"key":"10.1016\/j.repc.2025.12.010_bib0480","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/CIRCHEARTFAILURE.113.000577","article-title":"Correlates of quality of life in rural patients with heart failure","volume":"7","author":"Nesbitt","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0485","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s12325-017-0566-z","article-title":"Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease","volume":"34","author":"Covic","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.repc.2025.12.010_bib0490","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2012.05.036","article-title":"Health-related quality of life and anemia in hospitalized patients with heart failure","volume":"161","author":"Kraai","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212184","article-title":"Quality of life and its predictors among patients with chronic kidney disease: a hospital-based cross sectional study","volume":"14","author":"Kefale","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2025.12.010_bib0500","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-10-71","article-title":"Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment","volume":"10","author":"Pagels","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.repc.2025.12.010_bib0505","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000518668","article-title":"Health-related quality of life according to renal function: results from a nationwide health interview and examination survey","volume":"47","author":"Faulhaber","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.repc.2025.12.010_bib0510","first-page":"47","article-title":"Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes","volume":"18","author":"Weber","year":"2005","journal-title":"Manag Care Interface"},{"key":"10.1016\/j.repc.2025.12.010_bib0515","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41598-021-84554-6","article-title":"Health-related quality of life and its related factors in coronary heart disease patients: results from the Henan Rural Cohort study","volume":"11","author":"Mei","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.repc.2025.12.010_bib0520","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12955-021-01879-6","article-title":"The influencing factors of health-related quality of life among rural hypertensive individuals: a cross-sectional study","volume":"19","author":"Sang","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.repc.2025.12.010_bib0525","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025525","article-title":"Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial","volume":"9","author":"Ski","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.repc.2025.12.010_bib0530","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010988","article-title":"Association of diabetes mellitus with health status outcomes in young women and men after acute myocardial infarction: results from the VIRGO study","volume":"8","author":"Ding","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2025.12.010_bib0535","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017103","article-title":"Association of diabetes mellitus with health status outcomes in patients with peripheral artery disease: insights from the PORTRAIT registry","volume":"9","author":"Patel","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2025.12.010_bib0540","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2025.12.010_bib0545","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.12.010_bib0550","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0555","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2025.12.010_bib0560","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0565","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0570","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ejhf.2726","article-title":"Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0575","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0580","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003804","article-title":"Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker","volume":"10","author":"Besler","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0585","first-page":"129","article-title":"Galectin-3: a novel biomarker for the prognosis of heart failure","volume":"90","author":"Amin","year":"2017","journal-title":"Clujul Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0590","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2025.12.010_bib0595","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2016.09.019","article-title":"Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population","volume":"119","author":"Imran","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0600","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2016.09.019","article-title":"Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population","volume":"119","author":"Imran","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0605","article-title":"Prognostic value of serum galectin-3 in chronic heart failure: a meta-analysis","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2025.12.010_bib0610","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.12.010_bib0615","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713111","article-title":"The role of galectin-3 in heart failure \u2013 the diagnostic prognostic and therapeutic potential \u2013 where do we stand?","volume":"24","author":"Zaborska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.repc.2025.12.010_bib0620","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015405","article-title":"Levels and change in galectin-3 and association with cardiovascular events: the ARIC study","volume":"9","author":"Aguilar","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2025.12.010_bib0625","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2025.12.010_bib0630","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1016\/j.jacc.2018.09.076","article-title":"Longitudinal change in galectin-3 and incident cardiovascular outcomes","volume":"72","author":"Ghorbani","year":"2018","journal-title":"JACC"},{"key":"10.1016\/j.repc.2025.12.010_bib0635","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/heartjnl-2015-308975","article-title":"Serial galectin-3 and future cardiovascular disease in the general population","volume":"102","author":"van der Velde","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.repc.2025.12.010_bib0640","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in heart failure: an update of the last 3 years","volume":"14","author":"Gehlken","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.repc.2025.12.010_bib0645","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/cimb47050332","article-title":"Galectin-3 in cardiovascular health: a narrative review based on life's essential 8 and life's simple 7 frameworks","volume":"47","author":"Martuszewski","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.repc.2025.12.010_bib0650","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:05:05Z","timestamp":1778504705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255126000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0870255126000843"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2025.12.010","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}